Chemotherapy Plus HER-Vaxx Shows Efficacy in HER-2/Neu+,...

Chemotherapy Plus HER-Vaxx Shows Efficacy in HER-2/Neu+, Advanced/Metastatic Gastric or GEJ CancerJune 28, 2022Nichole TuckerIn patients with HER-2/Neu-overexpressing advanced/metastatic gastric or gastroesophageal junction (GEJ) cancer, HER-Vaxx (IMU-131) added to standard of care (SOC) chemotherapy demonstrated a 41.5% survival benefit compared with SOC chemotherapy alone.1HER-Vaxx is a single peptide structure that contains 3 individual B-cell epitope peptide sequences chosen from HER2/neu structure. The vaccine blocks HER2 signaling pathways, and it appears to be better than treatment with trastuzumab (Herceptin) monotherapy.According to findings from HERIZON clinical trial (NCT02795988), the hazard ratio for overall survival (OS) observed with HER-Vaxx and SOC was 0.585 (80% 2-sided CI, 0.368-0.930. The P-value was statistically significant at 0.066. The findings also suggested that HER-Vaxx does not add toxicity to SOC chemotherapy based on similar adverse events (AEs) observed between the treatment arms,“I am delighted to report that we have achieved this significant milestone for patients with advanced gastric cancer. The final analysis favored the survival outcome for HER-Vaxx and I note the Independent Data Monitoring Committee previously suggested to shorten the study by lowering the number of patients, said Leslie Chong, medical director and chief executive officer of Imugene,” in a press release.